News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GlaxoSmithKline and Genmab A/S Announce Start of Ofatumumab Phase III Combination Study in Non-Hodgkin’s Lymphoma
September 9, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON and COPENHAGEN, Denmark, Sept. 8, 2010 (GLOBE NEWSWIRE) -- Summary: GSK and Genmab announce the initiation of a Phase III study of ofatumumab in rituximab refractory patients with indolent B-cell non-Hodgkin's Lymphoma.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Sickle cell disease
Pfizer’s $5.4B GBT Bet Disappoints Again as Sickle Cell Therapy Fails in Phase III
August 18, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
Lilly Aims To Raise Europe Drug Prices in Response to Trumps’ Most Favored Nation Policy
August 14, 2025
·
3 min read
·
Annalee Armstrong
Obesity
Eli Lilly Keeps Obesity Pipeline Fresh With $1.3B Superluminal Partnership
August 14, 2025
·
1 min read
·
Dan Samorodnitsky
Pipeline
Schrödinger Cans Early-Stage Blood Cancer Drug After Two Patient Deaths
August 14, 2025
·
2 min read
·
Tristan Manalac
